Conference Proceedings

A phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases, in recurrent GBM patients.

D Reardon, T Cloughesy, C Conrad, M Prados, J Xia, W Mietlowski, M Dugan, P Mischel, H Friedman, A Yung

JOURNAL OF CLINICAL ONCOLOGY | AMER SOC CLINICAL ONCOLOGY | Published : 2005